Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on development of adaptable non-absorbed polymeric drugs to for congestive heart failure, chronic kidney disease, end stage renal disease and hypertension, closed a $36M Series B financing. Participants include Novartis Venture Funds, Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem.
Thanx for your patience as we [...]

AM-Pharma (The Netherlands) a clinical-stage pharmaceutical company focused on acute kidney injury and ulcerative colitis, closed a $39.8M Series D financing. Participants include Ysios Capital Partners, Kurma Life Science Partners, Abbott Ventures, Shire Ventures, BB Biotech Ventures, Idinvest Partners, Forbion Capital Partners and Inventages Venture Capital.

Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on cardiovascular and renal disorders, closed a $36M Series B financing, bringing the total round to $53M. Participants include Novartis Venture Funds, Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem.

InVasc Therapeutics (Tucker, GA) a clinical-stage biopharmaceutical company focused on the cardiometabloic diseases chronic kidney disease and atherosclerosis, closed a $3.1M Series A financing. Participants include Trois I Investments Industriels Internationaux.

Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on end stage renal disease, congestive heart failure, chronic kidney disease, and hypertension, closed a $21M Series B financing. Participants include AgeChem, CMEA Capital, ARCH Venture Partners, Sofinnova Ventures and Dow Venture Capital.

Reata Pharmaceuticals (Irving, TX) a clinical-stage small molecule company focused on inflammation modulation in chronic kidney disease, closed a $78M Series D financing. Participants include CPMG and Novo Ventures.

Action Pharma (Denmark) a clinical-stage biopharmaceutical company focused on acute kidney injury in patients undergoing cardiac surgery and inflammation, closed a $6.3M Series C financing. Participants include Sunstone Capital, Global Life Science Ventures, SLS Invest and InnovationsKapital.

Evolva (Switzerland) a clinical-stage synthetic biology small molecule company focused on proteinuri kidney and cardiovascular disease, closed a $15.2M Series B financing bringing the total round up to $42.3M. Participants include Wellington Partners, Aravis Venture Associates, Auriga Partners and Vinci Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Evolva (Switzerland) a clinical-stage synthetic biology small molecule company focused on proteinuri kidney and cardiovascular disease, closed a $27,5M Series B financing. Participants include Wellington Partners Venture Capital, Aravis Venture Associates, Auriga Partners and Vinci Capital.

Proteon Therapeutics (Waltham, MA) a clinical-stage biopharmaceutical company focused on a recombinant human elastase designed to improve arteriovenous fistula surgery outcomes in patients requiring chronic hemodialysis, closed on $12M, bringing the total Series B financing to $50M. Participants include Bessemer Venture Partners, Devon Park Bioventures, MPM Bio, Vectis Healthcare & Life Science Fund, TVM Capital, [...]

Proteon Therapeutics (Waltham, MA) a clinical stage biopharmaceutical company focused on renal and vascular disease, closed a $38M Series B financing. Participants include MPM Capital, Vectis Healthcare & Life Sciences Fund, TVM Capital, Skyline Ventures, Prism VentureWorks and Intersouth Partners.

Ardian (Palo Alto, CA) a clinical-stage medical device company focused on catheter-based treatment for hypertension, chronic kidney disease and heart failure, closed a $47M Series C financing. Participants include Medtronic, Emergent Medical Partners, Advanced Technology Ventures, Morgenthaler Ventures and Split Rock Partners.

Infacare Pharmaceutical (Trevose, PA) a specialty pharma company focused on the the acute neonatal and pediatric care closed a $28M Series financing. Participants include HealthCare Ventures, Longitude Capital, FirstMark Capital and Atlas Venture.